Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) SVP Sells 910 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 910 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $33,788.30. Following the completion of the transaction, the senior vice president now directly owns 91,511 shares of the company’s stock, valued at $3,397,803.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Paula Green also recently made the following trade(s):

• On Tuesday, April 2nd, Paula Green sold 229 shares of Twist Bioscience stock. The shares were sold at an average price of $32.74, for a total value of $7,497.46.
• On Wednesday, March 20th, Paula Green sold 200 shares of Twist Bioscience stock. The shares were sold at an average price of $33.52, for a total transaction of $6,704.00.
• On Wednesday, March 6th, Paula Green sold 600 shares of Twist Bioscience stock. The shares were sold at an average price of $37.43, for a total transaction of $22,458.00.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $41.40 on Thursday. Twist Bioscience Co. has a 1 year low of $11.81 and a 1 year high of $44.92. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of -12.32 and a beta of 1.64. The company’s 50 day simple moving average is $34.18 and its 200 day simple moving average is $31.59.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The business had revenue of $75.30 million during the quarter, compared to analyst estimates of $70.70 million. During the same quarter last year, the business earned ($1.06) EPS. The firm’s quarterly revenue was up 25.1% on a year-over-year basis. As a group, analysts anticipate that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Robert W. Baird raised their price target on Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. The Goldman Sachs Group upgraded Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $25.00 to $45.00 in a research report on Wednesday, January 17th. Scotiabank increased their price target on Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a research note on Monday. Barclays boosted their price objective on shares of Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Finally, Evercore ISI raised their price target on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $42.50.

Institutional Trading of Twist Bioscience

Several large investors have recently made changes to their positions in TWST. Charles Schwab Investment Management Inc. grew its holdings in Twist Bioscience by 3.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 442,504 shares of the company’s stock worth $8,965,000 after buying an additional 14,511 shares in the last quarter. State Board of Administration of Florida Retirement System increased its stake in shares of Twist Bioscience by 559.5% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 106,572 shares of the company’s stock worth $2,159,000 after purchasing an additional 90,413 shares during the last quarter. Dark Forest Capital Management LP raised its holdings in shares of Twist Bioscience by 121.3% in the 3rd quarter. Dark Forest Capital Management LP now owns 29,451 shares of the company’s stock worth $597,000 after purchasing an additional 16,142 shares during the period. Fox Run Management L.L.C. purchased a new position in Twist Bioscience in the third quarter valued at approximately $451,000. Finally, Citigroup Inc. lifted its position in shares of Twist Bioscience by 94.1% during the 3rd quarter. Citigroup Inc. now owns 264,204 shares of the company’s stock valued at $5,353,000 after buying an additional 128,098 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.